Trials
5 active
5 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Intramyocardial Injection of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) during coronary artery bypass grafting surgery”In the company’s words, NCT07496372 on ClinicalTrials.gov
- Tested for
- Heart Failure (3 trials), Ischemic Heart Failure (2 trials), Heart Failure At NYHA Stage III or IV, Advanced Heart Failure, CABG-patients
- Main trialPhase 3
- “The purpose of this clinical study is to evaluate the efficacy and safety of intramyocardial injection of human induced pluripotent stem cell-derived cardiomyocyte injection (HiCM-188) in patients with advanced heart failure (NYHA Class III-IV)”In the company’s words, NCT07496372 on ClinicalTrials.gov
- Other names
- iPSC-CMs
Other drugs for Heart Failure
- Balcinrenone/ dapagliflozinAstraZeneca · Phase 3
- DapagliflozinAstraZeneca · Phase 3
- Omecamtiv MecarbilCytokinetics · Phase 3
- InclisiranNovartis Pharmaceuticals · Phase 3
- EmpagliflozinBoehringer Ingelheim · Phase 3
- VicadrostatBoehringer Ingelheim · Phase 3
Coming up4
- 30 Jun 2027Phase 3 trial completes · ClinicalTrials.gov
- Dec 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Feb 2028Phase 1/2 trial completes · ClinicalTrials.gov
- 20 Oct 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 10 NovCompletion date moved: 2028-05 to 2028-02 · ClinicalTrials.gov NCT07646210
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Jun 2027 | A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV) | |
| Phase 1/2Active, not recruiting | 10 Nov 2026 | Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure | |
| Phase 1/2Not yet recruiting | Dec 2027 | IPSC-CMs Combined with LVAD or CABG for the Treatment of Heart Failure | |
| Phase 1/2Not yet recruiting | Feb 2028 | HiCM-188 Cell Therapy in Adults With Advanced Heart Failure Undergoing Heart Bypass Surgery | |
| Phase 1/2Not yet recruiting | 20 Oct 2028 | hiPSC-CMs-loaded Chitosan Patch to Treat Severe Chronic Ischemic Heart Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026